Haemonetics Corporation (NYSE: HAE) today announced that it has appointed Anila Lingamneni Executive Vice President and Chief Technology Officer, effective April 1, 2020. She will report directly to Chris Simon, Haemonetics' President and Chief Executive Officer.
Fund reveals 1st-quarter trades Continue reading...
It's only natural that many investors, especially those who are new to the game, prefer to buy shares in 'sexy' stocks...
By Chuck Royce, Lauren Romeo and Steven McBoyle Continue reading...
We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was trading at the 3150 level. We also told you to short the market and buy […]
Becton, Dickinson's (BDX) fiscal second-quarter results likely to reflect robust performance at BD Life Sciences. However, forex is likely to have remained a woe.
Haemonetics (HAE) expands its portfolio with the buyout of enicor. With the latter's whole blood coagulation testing system, the company will address a wider range of criticalities in medicine.
HAE earnings call for the period ending March 31, 2020.
Haemonetics (HAE) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Here we discuss three medical product stocks that are due to report soon and are likely to beat estimates on earnings, riding on a host of factors.
Haemonetics (HAE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Today we are going to look at Haemonetics Corporation (NYSE:HAE) to see whether it might be an attractive investment...
Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish fourth quarter and fiscal year 2020 financial results at 6:00 am EDT on Tuesday, May 5, 2020. The Company will hold a conference call with investors and analysts to discuss results and answer questions at 8:00 am EDT on May 5, 2020.
Haemonetics (HAE) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
To the annoyance of some shareholders, Haemonetics (NYSE:HAE) shares are down a considerable 31% in the last month...
Haemonetics (HAE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative hematology solutions to drive better patient outcomes, today announced that it has acquired enicor GmbH, a privately held manufacturer of a new generation whole blood coagulation testing system (ClotPro®), which is based in Munich, Germany. The ClotPro system is an innovative viscoelastic diagnostic device that offers more assays than any other hemostasis analyzer on the market. Under the terms of the transaction, Haemonetics has acquired all of the outstanding share capital of enicor GmbH.
Allscripts' (MDRX) Veradigm business line introduces new solution that will drive growing medication adherence and improve patient care.
Haemonetics' (HAE) fourth-quarter fiscal 2020 results reflect strong performance by Plasma segment despite dismal overall performance during the coronavirus-led crisis.
Q4 2020 Haemonetics Corp Earnings Call